2012 Scrip 100: Asia grows drug discovery footprint
This article was originally published in Scrip
The dramatic rise of clinical trial outsourcing over the past decade has been widely heralded. Although less frequently discussed, it is no less significant that pharma companies are increasingly farming out a wide variety of drug discovery processes to third-party providers. George Green looks at the market for outsourcing, with a special eye on China.
You may also be interested in...
The past decade has a seen a rapid expansion of pharma contract services markets that have outpaced pharmaceutical markets, often achieving double-digit year-on-year growth. George Green takes a look at the future for the contract drug manufacturer, and finds a scene not as settled as could be thought.
India's top 10 CMOs/CRAMS companies
The contract manufacturing market is set to grow by 40% over the next four years. George Green explains why China and India are ideally positioned to capitalise on this trend and the issues each country must overcome to gain the competitive edge.